简介:
- 作者: Tao Wang, Jian-Cheng Liao, Xu Wang, Qing-Song Wang, Kai-Ying Wan, Yi-Yi Yang, Qing He, Jia-Xuan Zhang, Gong Chen, and Wen Li
- 杂志: Neural Regen Res
- Doi: https://www.doi.org/10.4103/1673-5374.325747
- 出版日期: 2021 Dec 10
论文中使用的产品/服务
Quotation shows PackGene:For the in vivo experiments, single stranded adenovirusassociated viruses were used. A short version of the human glial fibrillary acidic protein (GFAP) promoter (681 bp, provided by PackGene Biotech) was used to construct pAAV GFAP::GFP and pAAV GFAP::NeuroD1-P2A-GFP. AAV serotype 9 (AAV9) was produced by PackGene Biotech. Iodixanol gradient (Merck/Sigma-Aldrich, St Louis, MO, USA) ultracentrifugation was used for AAV purification. All AAV used in this study was diluted in 0.001% Pluronic F-68 solution (Poloxamer 188 Solution, Caisson Laboratories, Smithfield, UT, USA).
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:Thirty adult male wild-type FVB/NJ mice (8–10 weeks old, ~25 g) were used for the in vivo experiments. Fifteen postnatal (P0–3) Sprague-Dawley rats were used for isolating primary astrocytes for in vitro experiments.
关于派真
作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。
